For women receiving oestrogen replacement therapy there is an increased risk of endometrial cancer, which can be countered by progesterone administration.
In women with an intact uterus it is recommended to add a progestogen for at least 12 days of each month, in accordance with the manufacturers’ recommendations.1
Progesterone Treatment
Besins Healthcare (UK) Ltd also provides a body identical micronised progesterone which greatly reduces the oestrogen-induced risk of endometrial cancer in women with an intact uterus.2,17,18
Utrogestan 100mg is a micronised progesterone indicated for17
- adjunctive use with oestrogen in postmenopausal women with an intact uterus, as hormone replacement therapy (HRT).
Utrogestan 100mg:
- is a body identical micronised progesterone2,17
- greatly reduces the oestrogen-induced risk of endometrial cancer in women with an intact uterus17,18
- is identical to the hormone produced by the body2,17
- The first micronised progesterone licensed for adjunctive use with oestrogen as HRT17,19-22
References:
1. Oestrogel Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/product/353/smpc Last accessed: October 2021.
2. Panay N, Post Reprod Health 2014;20(2):69-72.
17. Utrogestan Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/product/352/smpc Last accessed: May 2021.
18. Fournier A, et al. Am J Epidemiol 2014;180(5):508-517.
